Kia Michel, MD
Comprehensive Urology Studies ED Injections with Shockwave Therapy for Penile Girth Enhancement
September 23, 2024 15:34 ET | Comprehensive Urology
Comprehensive Urology of Los Angeles studies STUD Protocol for male enhancement in survivors of prostate cancer during Prostate Cancer Awareness Month.
Les conducteurs du DGD Montréal 2023 conduisent en profitant du voyage.
La « Distinguished Gentleman's Drive » fête sa quatrième année dimanche le 29 septembre 2024
September 23, 2024 07:30 ET | Movember Canada
TORONTO, 23 sept. 2024 (GLOBE NEWSWIRE) -- Le Distinguished Gentleman's Drive (DGD) est une célébration du style classique. C'est un événement de levée de fonds sur la route qui réunit des...
DGD Calgary Lead Image
The Distinguished Gentleman’s Drive Celebrates Its Fourth Year on Sunday, September 29, 2024
September 23, 2024 07:30 ET | Movember Canada
TORONTO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The Distinguished Gentleman’s Drive (DGD) is a celebration of classic style. It’s an on-road fundraising event that unites classic cars – aged 40 years...
Koelis Trinity
Koelis Announces Partnership and Initial Experience with DeepHealth for AI-powered Prostate MRI Interpretation and Guidance in Fusion Biopsy
September 20, 2024 09:07 ET | Koelis
Koelis finalizes partnership with Deep Health for AI-powered prostate MRI interpretation and guidance in fusion biopsy for prostate cancer.
Lantheus_Logo.png
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
September 15, 2024 08:45 ET | Lantheus Holdings, Inc.
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3%...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 15, 2024 03:00 ET | MacroGenics, Inc.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing...
MetasTx-Logo_HoRes.jpg
Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures
September 12, 2024 06:58 ET | MetasTx LLC
MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.
Tackling Prostate Cancer Disparities in Black Men
The National Civil Rights Museum Hosts Catalyst for Change Panel on Prostate Cancer Health Inequities in Black Men
September 10, 2024 16:22 ET | National Civil Rights Museum
Memphis, TN, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The National Civil Rights Museum (NCRM) is proud to present "Tackling Prostate Cancer Disparities in Black Men" as part of its Catalyst for Change...
Picture1.jpg
Curium Anuncia Que PYLCLARI®, un Innovador Trazador PET 18F-PSMA Indicado en Pacientes Con Cáncer De Próstata, Ya Está Disponible en España
September 10, 2024 04:30 ET | Curium US LLC
PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, líder mundial en medicina nuclear, ha anunciado hoy que PYLCLARI ® ya está disponible en España para pacientes con cáncer de próstata. PYLCLARI®...
Picture1.jpg
Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain
September 10, 2024 04:30 ET | Curium
CURIUM ANNOUNCES PYLCLARI® – AN INNOVATIVE 18F-PSMA PET TRACER INDICATED IN PATIENTS WITH PROSTATE CANCER – IS NOW AVAILABLE IN SPAIN